Guardant Health, Inc. board of directors increased the number of directors on the board to eight and appointed Steve E. Krognes as a class III director of the company, Effective June 30, 2022. Mr. Krognes will serve on the board for a term expiring at the 2024 annual meeting of stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal. In connection with his appointment to the board, Mr. Krognes was appointed to the audit committee of the board as chair and to the nominating and corporate governance committee of the board.

before joining the board, Mr. Krognes was the chief financial officer at Denali Therapeutics Inc. from October 2015 to April 2022. Mr. Krognes joined Denali from Genentech, Inc., where Steve served as Chief Financial Officer and a member of the Executive Committee from April 2009 to September 2015. Mr. Krognes also oversaw Genentech's Site Services organization between 2011 and 2015, and Genentech's IT organization between 2009 and 2011.

Steve chaired the Genentech Access to Care Foundation between 2009 and 2015. From January 2004 to April 2009, Mr. Krognes served as Head of Mergers & Acquisitions and a member of the Finance Executive Committee at Roche Holding AG. From July 2002 to December 2003, Mr. Krognes served as director of M&A at Danske Bank based in Norway.

Mr. Krognes currently serves as a member of the boards of directors of RLS Global, a Swedish life science company, and Gritstone bio, Inc., a biotechnology company. Mr. Krognes served as a board member of Corvus Pharmaceuticals between January 2016 and March 2021, the California Life Science Association between 2010 and 2015, and California Academy of Sciences from 2014 to 2018. He received his M.B.A. from Harvard Business School and his B.S. in Economics from The Wharton School of the University of Pennsylvania.